头颈鳞癌全身治疗:历史回顾与近期突破
OBJECTIVES: Despite dramatic developments in drugs established for other malignancies, historically there have been few novel systemic agents available for the management of head and neck squamous cell carcinoma (HNSCC).…
要点
- 帕博利珠单抗和纳武利尤单抗近期获FDA批准用于复发或转移性HNSCC。
核心结论
- 现代全身治疗策略已带来可测量的肿瘤学结局改善,支持进一步开展HNSCC药物研发。
研究设计与样本
- 历史性综述,数据来源为文献中可获得的病例系列和临床试验。
- 综述方法为评估评价HNSCC全身治疗的历史重要系列和试验。
主要发现
- 帕博利珠单抗和纳武利尤单抗近期获FDA批准用于复发或转移性HNSCC,其他适应证的试验正在进行中。
- 近期多项III期临床试验显示很大前景,促使几种新化疗药物和治疗策略被采用。
- 顺铂和5-氟尿嘧啶等较老药物继续在晚期HNSCC管理中发挥重要作用。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Despite dramatic developments in drugs established for other malignancies, historically there have been few novel systemic agents available for the management of head and neck squamous cell carcinoma (HNSCC). However, the last decade has observed increased interest in targeted therapies for HNSCC. In 2006, cetuximab became the first major drug for HNSCC to gain Food and Drug Administration (FDA) approval in 3 decades. Recently, both pembrolizumab and nivolumab gained FDA approval for treatment of recurrent or metastatic HNSCC, and trials for other indications in HNSCC are actively underway. As older agents including cisplatin and 5-fluorouracil continue to play a significant role in the management of advanced HNSCC, an understanding of their legacy is paramount. This historical review is not meant to exhaustively catalog every finding relating to HNSCC systemic therapy, but rather is meant to highlight important advances. DATA SOURCES: Case series and clinical trials available in the literature. REVIEW METHODS: Historically significant series and trials evaluating HNSCC systemic therapy were evaluated. RESULTS: Standard regimens employed today are largely comprised of drugs discovered over 4 decades ago, although a number of recent phase III clinical trials have shown great promise, leading to the adoption of several new chemotherapeutic agents and treatment strategies. CONCLUSIONS: These findings reinforce the importance of supporting further HNSCC drug discovery as modern treatment strategies using systemic therapy have resulted in measurable improvements in oncologic outcomes. Laryngoscope, 127:2565-2569, 2017.
引用
- Blasco MA, Svider PF, Raza SN, et al. Systemic therapy for head and neck squamous cell carcinoma: Historical perspectives and recent breakthroughs. Laryngoscope. 2017. PMID: 28581126. doi:10.1002/lary.26629
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。